VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · IEX Real-Time Price · USD
2.530
+0.010 (0.40%)
At close: May 1, 2024, 4:00 PM
2.990
+0.460 (18.18%)
After-hours: May 1, 2024, 5:00 PM EDT

VYNE Therapeutics Revenue

In the year 2023, VYNE Therapeutics had annual revenue of $424.00K, a decrease of -11.11%. Revenue in the quarter ending December 31, 2023 was $76.00K with 1,166.67% year-over-year growth.

Revenue (ttm)
$424.00K
Revenue Growth
-11.11%
P/S Ratio
84.13
Revenue / Employee
$42,400
Employees
10
Market Cap
35.67M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023424.00K-53.00K-11.11%
Dec 31, 2022477.00K-454.00K-48.76%
Dec 31, 2021931.00K-20.06M-95.57%
Dec 31, 202020.99M20.55M4,638.83%
Dec 31, 2019443.00K-3.15M-87.68%
Dec 31, 20183.60M-987.00K-21.54%
Dec 31, 20174.58M3.91M579.82%
Dec 31, 2016674.00K--
Dec 31, 20150--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
LENSAR 42.16M
Precision Optics Corporation 19.22M
electroCore 16.03M
Co-Diagnostics 6.81M
Evogene 5.64M
Marker Therapeutics 3.31M
IGC Pharma 1.22M
Revenue Rankings